Join to View Full Profile
200 First Street SWRochester, MN 55905
Dr. Horna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Anatomic and clinical hematopathologist with work experience in morphology, wet hematopathology, 10-color flow cytometry, fluorescent in-situ hybridization, and immune receptor gene rearrangement studies. My research interests include the development and analysis of high-dimensional flow cytometry assays, molecular profiling by next generation sequencing, laboratory diagnosis of cutaneous lymphomas, and correlative studies for clinical trials.
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematopathology, 2010 - 2011
University of Texas Southwestern Medical CenterResidency, Pathology-Anatomic and Clinical, 2006 - 2010
University of South Florida College of MedicinePost-Doctoral Fellowship, 2002 - 2006
Cayetano Heredia UniversityClass of 2002
Certifications & Licensure
FL State Medical License 2011 - 2027
MN State Medical License 2016 - 2025
WI State Medical License 2010 - 2011
NM State Medical License 2007 - 2008
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- Appropriate interpretation of TRBC1-dim positive subsets in T-cell immunophenotyping by flow cytometry.Min Shi, Matthew J Weybright, Gregory E Otteson, Dragan Jevremovic, Horatiu Olteanu
Cytometry. Part B, Clinical Cytometry. 2025-03-01 - Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.Saurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, Horatiu Olteanu, Francis Buadi
Blood Cancer Journal. 2025-02-18 - Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.Mathieu Ferrari, Farhaan Parekh, Paul Maciocia, Pedro Horna, Simon Thomas
Nature Communications. 2025-01-29
Other Languages
- Spanish
External Links
- LinkedInhttp://www.linkedin.com/in/pedrohorna
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
